New cancer therapies in 2022 achieving unprecedented remissions - reviewing a year of hope
Including gene editing, immunotherapy, modified viruses, vaccines, personalised medicine, and nanotechnology
Join the club for FREE to access the whole archive and other member benefits.
Consultant urologist at University College London Hospital
Dr Alistair Grey is a Urologist, physician who has practice in University College Hospital at Westmoreland Street in London. Alistair Grey, FRCS (Urol), University College London, London, UK, discusses the results of the CADMUS trial (ISRCTN38541912): a prospective paired cohort trial comparing multiparametric ultrasound (mpUSS) with multiparametric MRI (mpMRI) targeted biopsies in the detection of clinically significant prostate cancer. 306 patients underwent both mpUSS and mpMRI independently, and those with a positive result in either test were advised to undergo targeted biopsies. The performance of mpUSS was comparable to that of mpMRI, with an agreement in the detection of clinically significant prostate cancer of over 91%. mpUSS detected around 4% less clinically significant prostate cancer. Using both scans together increased overall and clinically significant cancer detection. The findings from the CADMUS trial may lead to the deployment of mpUSS as a cheaper, more accessible alternative to mpMRI for the detection of prostate cancer and may lead to the use of both technologies, in combination, to improve diagnosis.
Visit website: https://www.nhs.uk/profiles/consultant/4717896
See also: University College London Hospitals NHS Foundation Trust - NHS foundation trust based in London, UK
Details last updated 20-Jan-2023
Including gene editing, immunotherapy, modified viruses, vaccines, personalised medicine, and nanotechnology